3-D Matrix

What 3-D Matrix does

3-D Matrix is a global medical device company commercializing a self-assembling peptide technology platform originally discovered at MIT in the 1990s by Shuguang Zhang and licensed exclusively to the firm. Its core products — PuraStat, PuraBond, PuraShield, and PuraGel — are synthetic hemostatic agents based on RADA16 peptide sequences (arginine-alanine-aspartic acid-alanine, repeated four times) that self-assemble into transparent, nanofibrous 3D hydrogels mimicking human extracellular matrix upon exposure to physiological ions and pH. A separate PuraMatrix laboratory product serves life science research as the first commercial synthetic extracellular matrix scaffold for 3D cell culture, and a pipeline asset (NU-MAX) is in first-in-human clinical trials for intracranial neurosurgery. The company serves healthcare professionals in gastroenterology, cardiac surgery, ear/nose/throat, and urology, with clinical evidence including 98.2% hemostatic efficacy in endonasal surgery across 167 patients and KOL endorsements from leading academic centers in the UK, US, Germany, Spain, and Japan.

The firm is organized as 3-D Matrix Ltd., publicly listed on the Japanese Stock Exchange since 2011 with group headquarters in Tokyo, and operates wholly-owned subsidiaries across the United States (Newton, MA), France (Lyon, European HQ), United Kingdom, Netherlands, Singapore, Australia, China, and Hong Kong. Revenue is generated primarily through hardware sales of prefilled-syringe medical devices and applicator accessories (PuraStat nozzle systems Type-E and Type-L), supplemented by licensing royalties from manufacturing partners such as FUSO Pharmaceutical Industries. Distribution follows a hybrid model: direct sales in the US via phone/email ordering, and a global distributor network across Europe, the Middle East, and Asia — including a flagship partnership with Fujifilm Healthcare covering European and Middle Eastern GI endoscopy markets. The company holds FDA 510(k) clearance for PuraStat-OM, CE marking (Class IIa) for European distribution, and Japan NHI reimbursement listing for PuraStat (effective December 2021). With 11–50 employees, the firm relies heavily on clinical-evidence-driven marketing through medical conferences (ACG, ESGE, HITEC), KOL-led education, and peer-reviewed case studies rather than mass-market promotion.

Name

3-D Matrix

Legal name

3-D Matrix Europe SAS

Website

https://3dmatrix.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

3-D Matrix is a publicly listed Japanese medical device company that commercializes MIT-licensed self-assembling peptide technology, selling synthetic hemostatic products (PuraStat, PuraBond, PuraShield) to gastroenterology, cardiac surgery, and ENT specialists globally through direct sales and a distributor network.

Ownership category

akta.pro rank

Product category

Hemostatic medical devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAHAFAJ

Thrombectomy, Embolic Protection & Stroke Intervention Devices

Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

SECONDARYHLAGAGAI

Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

• Hemostatic medical devices
• Self-assembling peptides
• Surgical hemostasis products
• Endoscopic bleeding control
• Synthetic extracellular matrix

Headquarters

HQ city

Caluire-et-cuire

HQ country

France

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales - Hemostatic Products: Sale of PuraStat, PuraBond, and PuraShield hemostatic medical devices for surgical and endoscopic procedures. Products are sold as prefilled syringes and accessories (nozzle systems) through direct sales and distribution network.
2. Laboratory Solutions: PuraMatrix laboratory product sold for life science research, pharmaceutical drug discovery, and bioproduction as cell culture media. Not a medical device, sold separately for research applications.
3. Licensing Royalties: Manufacturing license agreements with partners such as FUSO Pharmaceutical Industries, generating licensing revenue from product manufacturing.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

3-D Matrix develops, manufactures, and sells hemostatic medical devices based on proprietary self-assembling peptide (RADA16) technology. Its core commercial products are synthetic hydrogel hemostats — PuraStat, PuraBond, PuraShield, and PuraGel — supplied in ready-to-use prefilled syringes for bleeding control during and after GI endoscopy, cardiac surgery, ENT, and urological procedures. The company also sells PuraMatrix, a separate synthetic extracellular matrix product for life-science research, drug discovery, and bioproduction.

Product overview

3-D Matrix offers a portfolio of medical devices based on self-assembling peptide technology, originating from MIT research. The core products include PuraStat, PuraBond, and PuraShield - synthetic hemostatic agents using RADA16 peptide sequences that self-assemble into 3D hydrogels mimicking extracellular matrix. Supporting accessories include endoscopic (Type-E) and laparoscopic (Type-L) nozzle systems for delivery. A separate laboratory product line includes PuraMatrix® for life science research applications. The technology platform uses synthetic amino acids (1% w/v) in water that self-assemble under physiological conditions into nanofibrous 3D hydrogels.

Differentiator

Problem solved

Functional benefit

Brands

• PuraStat: Synthetic hemostatic agent in prefilled syringe form for GI bleeding, ESD/EMR procedures, and radiation proctitis
• PuraBond
• PuraShield
• PuraMatrix
• PuraGel
• NU-MAX

Products and services

• PuraStat Synthetic hemostatic material in prefilled syringe form based on self-assembling RADA16 peptide technology. Provides transparent hemostasis during GI procedures for intraprocedural and delayed bleeding control, adjunct/bridge/prophylactic therapy for venous bleeding, prevention of post-procedure bleeding in GI bleeding, and symptomatic management of rectal mucositis including radiation proctitis. Indicated for healthcare professionals performing gastrointestinal endoscopic procedures.
• PuraBond Self-assembling peptide hemostatic product for surgical applications, used particularly in cardiac surgery and ENT procedures. Forms a transparent 3D hydrogel mechanical barrier for hemostasis.
• PuraShield Medical device for ENT (Ear, Nose & Throat) applications, providing hemostatic properties using self-assembling peptide technology for ENT surgeons and specialists.
• PuraGel Synthetic hemostatic hydrogel based on self-assembling peptide technology (RADA16) used in sinus surgery and other ENT procedures including concha bullosa resection, inferior turbinate reduction, septoplasty, and septal perforation repair. Demonstrated by clinical expert Dr. Jordan Pritikin in Chicago, IL.
• PuraMatrix® First commercial synthetic extracellular matrix (ECM) scaffold based on self-assembling peptides for life-science research, pharmaceutical drug discovery, and bioproduction. Not a medical device. Used to create defined three-dimensional microenvironments for cell culture experiments. Standard amino acids (1% w/v) and 99% water forming nanometer-scale fibrous 3D hydrogel.
• Applicators (Nozzle Systems Type-E and Type-L) Class IIa medical device accessory nozzle systems for PuraStat. Type-E is an endoscopic applicator; Type-L is a laparoscopic applicator. Both connect via Luer-Lock to the PuraStat prefilled syringe for endoscopic or laparoscopic delivery. CE marked under European Council Directive 93/42/EEC, manufactured by Top Corporation in Japan and distributed by 3-D Matrix Europe SAS.

Quantifiable outcome

• 98.2% hemostatic efficacy in endonasal surgery study (167 patients, 9 surgeons)
• +3 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, flagship and minor.

• FUSO Pharmaceutical Industries, Ltd.coreOEM/ Whitelabel/ Licensing Partner · 29 June 2022Manufacturing license agreement for absorbable local hemostatic material using self-assembling peptides. Osaka-based pharmaceutical company (established 1937, ¥10,758 million capital, 1,344 employees) with extensive track record manufacturing the product. Agreement enables stable product supply and production scale-up.
• Pharmpur GmbHcoreOEM/ Whitelabel/ Licensing Partner · 16 December 2021Manufacturing and service agreement for European production. Manufacturing has started in Europe, complementing the Japanese manufacturing base to ensure stable supply to the European market.
• FujifilmflagshipChannel Partner/ Reseller/ DistributorStrategic collaboration with Fujifilm Healthcare and its distributors to cover markets across Europe and the Middle East. Includes co-hosting events and training sessions for healthcare professionals on GI procedures.
• Top CorporationcoreOEM/ Whitelabel/ Licensing PartnerLegal manufacturer of PuraStat applicators. Tokyo-based company (19-10 Senjunakai-cho, Adachi-ku, Tokyo) manufacturing nozzle systems Type-E and Type-L for endoscopic and laparoscopic applications.
• MPS Medical Product Service GmbHminorChannel Partner/ Reseller/ DistributorGerman-based medical product service company involved in distribution of applicator products. Located at Borngasse 20, 35619 Braunfels, Germany.
• Aquilant (part of HC21 group)minorChannel Partner/ Reseller/ DistributorEuropean distributor awarded for highest growth in FY2021 during 3-D Matrix distributor meeting in Barcelona. Part of HC21 group serving European healthcare markets.
• LorenzattominorChannel Partner/ Reseller/ DistributorEuropean distributor awarded for highest market penetration during 3-D Matrix distributor meeting in Barcelona.
• MedVedminorChannel Partner/ Reseller/ DistributorEuropean distributor awarded for being best company at introducing PuraStat into the Czech Republic market for the first time.
• Dr. Eduardo AlbénizcoreStrategic or Co-development PartnerKey Opinion Leader from Complejo Hospitalario de Navarra, Spain. Shared clinical experiences on using PuraStat during GI procedures at distributor training events, providing expert perspective on unmet clinical needs.
• Dr. Sergio CodacoreStrategic or Co-development PartnerKey Opinion Leader from Queen's Hospital and King's George's Hospital, UK. Provided interactive training for distributors on clinical experiences using hemostatic agent for GI procedures.
• Massachusetts Institute of Technology (MIT)coreStrategic or Co-development PartnerOriginal licensor of self-assembling peptide technology. Shuguang Zhang's discovery at MIT in the 1990s led to the founding of 3-D Matrix Inc. in Boston in 2001 with exclusive global license from MIT.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• B. Braun Melsungen: B. Braun markets a portfolio including surgical hemostats (e.g., Lyostypt) as part of its broader surgical and wound-care franchise across Europe, with overlap in the same hospital channels 3-D Matrix targets.
• Becton, Dickinson and Company (BD): BD's Surgery division markets a broad portfolio of biosurgical products including hemostats and sealants (e.g., Progel). A larger incumbent operating across multiple surgical adjacencies that overlap with 3-D Matrix's specialty applications.

Others

• Olympus Medical: Olympus is the dominant GI endoscopy equipment vendor whose installed base creates the procedure demand for endoscopic hemostasis products like PuraStat. Strategic channel partner ecosystem rather than a direct competitor.
• Corning Life Sciences: Corning sells Matrigel and other 3D cell-culture matrices for life-science research, directly comparable to 3-D Matrix's PuraMatrix product for research and bioproduction use cases.

Emerging players

• Actamax Surgical Materials: Actamax (a DSM Biomedical/Braun joint venture) developed DuraSeal-adjacent polymer sealants for surgery. Comparable as another specialty-focused synthetic sealant challenger in adjacent surgical sealing indications.
• Cohera Medical: Cohera develops synthetic, biocompatible tissue adhesives and sealants for surgical use, comparable in technology philosophy to 3-D Matrix's self-assembling peptide approach but focused on different anatomic sites.
• CorMatrix Cardiovascular: CorMatrix develops biomaterials for cardiac tissue repair and regeneration. Comparable to 3-D Matrix's cardiac surgery product line (PuraBond) and adjacent to its self-assembling peptide scaffold science.

Direct peers

• Integra LifeSciences: Integra sells DuraSeal and other neurosurgical sealants/hemostats, directly comparable to 3-D Matrix's NU-MAX for intracranial hemostasis and overlapping with PuraStat applications in surgical sealing.
• Baxter International: Baxter's BioSurgery division sells FloSeal and Tisseel, the leading gelatin- and fibrin-based hemostatic agents. PuraStat and PuraBond compete head-to-head with these products in the same surgical hemostasis procedure codes.
• Ethicon (Johnson & Johnson MedTech): Ethicon markets SURGICEL, EVICEL, and other hemostatic and tissue-sealing products within J&J's surgical franchise. They are direct competitors in cardiac, ENT, and general surgery hemostasis where PuraBond is positioned.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCAL-yW5rvDD64iGxj9gJ73g
• Xx.com/3dm_emea
• Facebookfacebook.com/3dmatrixemea

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3-D Matrix